Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes...

|By:, SA News Editor

Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes firms MannKind (MNKD +6.55%) and Vivus (VVUS +0.4%) could be acquisition targets as well. It's worth noting, though, that King's speculation accompanies a mea culpa for being wrong about Amylin, whose assets he described as "mediocre."